| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3236 |
| Trial ID | NCT05618925 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | CD19t-haNK |
| Co-treatment | Rituximab |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | ImmunityBio, Inc. |
| Other ID(s) | QUILT-3.092 |
| Cohort1: CD19 t-haNK+rituximab | |||||||||
|
|||||||||
| Cohort2: CD19 t-haNK+rituximab+N-803 | |||||||||
|
|||||||||